Comparison · NCT00636636-74e63edc
G-ER vs Placebo: Patient Global Impression of Change (PGIC)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. G-ER vs Placebo: Patient Global Impression of Change (PGIC). Trial comparisons, record NCT00636636-74e63edc. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00636636-74e63edc
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.427 | 0.364 | 0.493 | wilson | |
| Risk in group 2 | 0.335 | 0.277 | 0.398 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0925 | 0.00281 | 0.18 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.28 | 1.01 | 1.62 | log | |
| Odds ratio, group 1 over group 2 | 1.48 | 1.01 | 2.17 | log | |
| Number needed to treat, for one more participant with the outcome on G-ER than on Placebo | 10.8 | 5.55 | 356 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | G-ER | Gabapentin Extended Release 1800 mg once daily (qd); 300 mg and 600 mg tablets, oral dosing | 94 | 220 | OG000 |
| Group 2 | Placebo | Placebo 1800 mg once daily (qd); 300 mg and 600 mg sugar pills, oral dosing | 77 | 230 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Patient Global Impression of Change (PGIC)
- Description
Patient self-assessment of how much pain had changed at end of treatment period (Week 10) compared to pain at baseline; scored on 7-point numerical rating scale (where 1 = very much improved, 7 = very much worse). Results presented as number of participants categorized at end of treatment (Week 10) as very much improved (score = 1) or much improved (score = 2).
- Time frame
- 10 weeks
- Population
- ITT, BOCF
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy of Gabapentin in Postherpetic Neuralgia
- NCT number
- NCT00636636
- Phases
- PHASE3
- Conditions
- Neuralgia,Postherpetic
- Interventions
- Gabapentin Extended Release tablets, Placebo
- Lead sponsor
- Depomed
- Results first posted
- 2012-01-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00636636?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00636636-74e63edc